Key result
DOACs linked to ~63% less major bleeding versus LMWH in brain tumor patients.
Why the study?
Brain tumor patients frequently need anticoagulation for high thromboembolic risk, but data supporting the use and safety of DOACs in this population are limited.
Do direct oral anticoagulants (DOACs) reduce major bleeding and intracranial hemorrhage compared to low molecular weight heparin (LMWH) in patients with primary and metastatic brain tumors?
Population
125 patients with primary and metastatic brain tumors on anticoagulation
Comparison
DOACs vs LMWH
Design
Single-center retrospective chart review
Authors
Loading...
May support DOAC use over LMWH for lower bleeding in brain tumors; leaves open confirmation by RCTs before practice change.
Cohort (n=125)
No
Do direct oral anticoagulants (DOACs) reduce major bleeding and intracranial hemorrhage compared to low molecular weight heparin (LMWH) in patients with primary and metastatic brain tumors?
Absolute Event Rate: 9.6% vs 26%
p-value: p=0.03
In patients with brain tumors requiring anticoagulation, DOACs are associated with a significantly lower rate of major bleeding compared to LMWH, supporting their safety in this high-risk population.
Swartz et al. (2021) conducted a cohort in Primary and metastatic brain tumors (n=125). Direct oral anticoagulants (DOACs) vs. Low molecular weight heparin (LMWH) was evaluated on Major bleeding (p=0.03). In patients with brain tumors, DOACs were associated with a significantly lower rate of major bleeding compared to LMWH (9.6% vs 26%, p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: